Background: The SURMOUNT Research Program
The SURMOUNT (Study of tirzepatide in participants with obesity or overweight) program represents one of the most comprehensive clinical research initiatives in metabolic medicine. Comprising multiple Phase 3 trials, the program has generated substantial data on the effects of dual GIP/GLP-1 receptor agonism on body composition and metabolic parameters.
Tirzepatide: Structural Innovation
Tirzepatide is a 39-amino acid synthetic peptide based on the native GIP sequence with modifications enabling GLP-1 receptor co-agonism. The molecule incorporates a C20 fatty diacid attached via aminoisobutyric acid (Aib) linker for albumin binding, a half-life of approximately 5 days (once-weekly dosing), and balanced dual agonism with approximately equal potency at GIP and GLP-1 receptors.
5×
greater potency at GIPR compared to native GIP, with preserved GLP-1R potency
SURMOUNT-1: Primary Research Findings
SURMOUNT-1 (NCT04184622) enrolled 2,539 adults with BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, without type 2 diabetes. The study ran for 72 weeks as a randomised, double-blind, placebo-controlled trial evaluating doses of 5mg, 10mg, and 15mg weekly.
22.5%
mean body weight reduction at 15mg dose vs 2.4% placebo — SURMOUNT-1, Jastreboff et al., 2022
Results across dose groups: 5mg — 15.0% mean weight change, 31% achieved ≥20% loss; 10mg — 19.5%, 50% achieved ≥20% loss; 15mg — 20.9%*, 57% achieved ≥20% loss. *Estimated treatment difference vs placebo: -18.5%.
SURMOUNT-2: Type 2 Diabetes Population
SURMOUNT-2 examined tirzepatide in adults with both obesity and type 2 diabetes, a population where weight reduction is historically more challenging.
15.7%
mean weight reduction at 15mg in participants with type 2 diabetes (SURMOUNT-2), compared to 13.9% with GLP-1 monotherapy
SURMOUNT-3 and SURMOUNT-4: Maintenance Research
- —SURMOUNT-3: Evaluated tirzepatide following intensive lifestyle intervention lead-in period, demonstrating additional 21.1% weight reduction from lifestyle-adjusted baseline
- —SURMOUNT-4: Withdrawal study confirming weight regain upon discontinuation, supporting chronic administration requirement
Metabolic Parameter Changes
Beyond body weight, SURMOUNT data demonstrated significant changes in: waist circumference -14.4cm at 15mg, HbA1c -2.1% in diabetic subgroups, fasting LDL -16%, triglycerides -25%, and systolic blood pressure -7.2mmHg.
Research Implications
The SURMOUNT program data has established dual GIP/GLP-1 agonism as a distinct and superior research paradigm compared to GLP-1 monotherapy, providing the scientific rationale for continued exploration of multi-receptor targeting strategies in metabolic research.